HILTON LONDON OLYMPIA LONDON, UK

OCTOBER 22-24 2018

View Full Event Program

View the full event program for Precision CRISPR Drug Discovery & Gene Therapy Europe 2018 with detailed agenda, workshop details, expert speaker line-up, 18+ focused case studies and attendance breakdown.

Capture

AGENDA HIGHLIGHTS

Take a look at the agenda highlights below. To view all 18 case-studies, roundtable sessions and workshop details view full event program.

CASE STUDY: Gene Repair in Human Hematopoietic Stem Cells

  • A systematic approach for generating knock-ins in stem cells
  • Identifying and improving the precision of HDR events
  • Use of live imaging and gene editing to explore cell states

Jacob Corn
Professor of Genome Biology
ETH Zurich

CASE STUDY: Utilising CRISPR Screen in Difficult Cells, Studies of Primary Immune Cells

Fredrik Wermeling
Assistant professor
Karolinska Institue

CASE STUDY: Mouse Genome Editing Using CRISPR/Cas9 Technology

  • Different forms of Cas9 and gRNA used for genome editing
  • Targeted gene disruption and deletion to generate gene KO mice
  • Site-specific transgene integration to generate gene KI mice

Lin Wu
Director
Genome Modification Facility at Harvard University

CASE STUDY: Detection of in vitro and ex vivo Cellular indel Profiles and Dynamics Induced By Different CRISPR/Cas9 Delivery Formats

  • Methodologies for absolute identification of cellular Cas9 induced indel events
  • Plasmid-, piggyback-, lenti- and RNP -Cas9 delivery formats
  • Indel formation dynamics and profiles induced by various CRISPR/Cas9 delivery methods
  • In vitro and ex vivo Indel formation, dynamics and profiles induced by various CRISPR/ Cas9 delivery formats

Eric Paul Bennet
Associate professor
University of Copenhagen

CASE STUDY: Modelling neurodegenerative disease using isogenic pairs of human iPSCs generated by CRISPR/Cas9

  • Efficient production of isogenic iPSC lines using CRISPR RNP and high throughput
    sequencing
  • Use of isogenic cell pairs to understand the causative genetic aberrations, independent
    of genetic background
  • Identification of perturbed cellular stress responses in an iPSC-derived model of Parkinson’s disease (alpha-synuclein triplication)

Andrew Bassett
Head of Research
(Cellular Operations)

Wellcome Trust Sanger Institute

CASE STUDY: Precise Genome Engineering to Empower Drug Discovery

  • Pooled and arrayed CRIPSR screening for Target Identification
  • Target Validation in CRISPR enabled cell and animal models of disease
  • Precision medicine approaches in Oncology and beyond

Barry Rosen
VP & & Senior Principal Scientist
Astra Zeneca